Polynuclear platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma

Neuro-Oncology

Volumn 8, Issue 3, 2006, Pages 215-226

  Billecke, Christine ^a   Finniss, Susan ^a   Tahash, Laura ^a   Miller, Cathie ^a   Mikkelsen, Tom ^a   Farrell, Nicholas P ^b   Bögler, Oliver ^a,c  

^a HENRY FORD HOSPITAL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapy; ERK; Extracellular signal regulated kinase; G2 M arrest; Glioma; Multinuclear platinum

Indexed keywords

BBR 3464; BBR 3571; BBR 3610; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PLATINUM DERIVATIVE; SPERMIDINE DERIVATIVE; SPERMINE DERIVATIVE; SURVIVIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER MODEL; CANCER SIZE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME PHOSPHORYLATION; FEMALE; GLIOMA; GLIOMA CELL; MOUSE; NONHUMAN; NUDE MOUSE; TUMOR XENOGRAFT; ANIMAL; CELL CULTURE; CELL CYCLE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG SCREENING; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GLIOMA; MICE; MICE, NUDE; ORGANOPLATINUM COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 33750630841     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1215/15228517-2006-004     Document Type: Article

References (41)

1. Altieri, D.C. (2001) The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol. Med. 7, 542-547.
2. Altieri, D.C. (2003) Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 3, 46-54.
3. Bacus, S.S., Gudkov, A.V., Lowe, M., Lyass, L., Yung, Y., Komarov, A.P., Keyomarsi, K., Yarden, Y., and Seger, R. (2001) Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 20, 147-155.
4. Bartek, J., and Lukas, J. (2003) Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3, 421-429.
5. Brabec, V., Kasparkova, J., Vrana, O., Novakova, O., Cox, J.W., Qu, Y., and Farrell, N. (1999) DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent. Biochemistry 38, 6781-6790.
6. Farrell, N. (2000) Polynuclear charged platinum compounds as a new class of anticancer agents. Toward a new paradigm. In: Kelland, L.R., and Farrell, N. (Eds.), Platinum-Based Drugs in Cancer Therapy. Totowa, N.J.: Humana Press.
7. Farrell, N. (2004) Polynuclear platinum drugs. Met. Ions Biol. Syst. 42, 251-296.
8. Gatti, L., Beretta, G.L., Carenini, N., Corna, E., Zunino, F., and Perego, P. (2004) Gene expression profiles in the cellular response to a multinuclear platinum complex. Cell Mol. Life Sci. 61, 973-981.
9. Gourley, C., Cassidy, J., Edwards, C., Samuel, L., Bisset, D., Camboni, G., Young, A., Boyle, D., and Jodrell, D. (2004) A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer. Cancer Chemother. Pharmacol. 53, 95-101.
10. 4+ (BBR 3464) with its noncovalent congeners. Mol. Pharmacol. 69, 666-672.
11. Harris, A.L., Yang, X., Hegmans, A., Povirk, L., Ryan, J.J., Kelland, L., and Farrell, N.P. (2005) Synthesis, characterization, and cytotoxicity of a novel highly charged trinuclear platinum compound. Enhancement of cellular uptake with charge. Inorg. Chem. 44, 9598-9600.
12. Hayakawa, J., Ohmichi, M., Kurachi, H., Ikegami, H., Kimura, A., Matsuoka, T., Jikihara, H., Mercola, D., and Murata, Y. (1999) Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J. Biol. Chem. 274, 31648-31654.
13. Hegmans, A., Berners-Price, S.J., Davies, M.S., Thomas, D.S., Humphreys, A.S., and Farrell, N. (2004) Long range 1,4 and 1,6-interstrand cross-links formed by a trinuclear platinum complex. Minor groove preassociation affects kinetics and mechanism of cross-link formation as well as adduct structure. J. Am. Chem. Soc. 126, 2166-2180.
14. Hirose, Y., Katayama, M., Berger, M.S., and Pieper, R.O. (2004) Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide. J. Neurosurg. 100, 1060-1065.
15. Hirose, Y., Katayama, M., Mirzoeva, O.K., Berger, M.S., and Pieper, R.O. (2005) Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res. 65, 4861-4869.
16. Ishiyama, M., Tominaga, H., Shiga, M., Sasamoto, K., Ohkura, Y., and Ueno, K. (1996) A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol. Pharm. Bull. 19, 1518-1520.
17. Jodrell, D.I., Evans, T.R., Steward, W., Cameron, D., Prendiville, J., Aschele, C., Noberasco, C., Lind, M., Carmichael, J., Dobbs, N., Camboni, G., Gatti, B., and De Braud, F. (2004) Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastrooesophageal adenocarcinoma. Eur. J. Cancer 40, 1872-1877.
18. Kasparkova, J., Zehnulova, J., Farrell, N., and Brabec, V. (2002) DNA interstrand cross-links of the novel antitumor trinuclear platinum complex BBR3464: Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair. J. Biol. Chem. 277, 48076-48086.
19. Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., Louis, D.N., Christiani, D.C., Settleman, J., and Haber, D.A. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139.
20. Manzotti, C., Pratesi, G., Menta, E., Di Domenico, R., Cavalletti, E., Fiebig, H.H., Kelland, L.R., Farrell, N., Polizzi, D., Supino, R., Pezzoni, G., and Zunino, F. (2000) BBR 3464: A novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin. Clin. Cancer Res. 6, 2626-2634.
21. McGregor, T.D., Hegmans, A., Kasparkova, J., Neplechova, K., Novakova, O., Penazova, H., Vrana, O., Brabec, V., and Farrell, N. (2002) A comparison of DNA binding profiles of dinuclear platinum compounds with polyamine linkers and the trinuclear platinum phase II clinical agent BBR3464. J. Biol. Inorg. Chem. 7, 397-404.
22. Oehlsen, M.E., Qu, Y., and Farrell, N. (2003) Reaction of polynuclear platinum antitumor compounds with reduced glutathione studied by multinuclear (1H, 1H-15N gradient heteronuclear single-quantum coherence, and 195Pt) NMR spectroscopy. Inorg. Chem. 42, 5498-5506.
23. Okhrimenko, H., Lu, W., Xiang, C., Ju, D., Blumberg, P.M., Gomel, R., Kazimirsky, G., and Brodie, C. (2005) Roles of tyrosine phosphorylation and cleavage of protein kinase Cδ in its protective effect against tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis. J. Biol. Chem. 280, 23643-23652.
24. Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M.J., Sellers, W.R., Johnson, B.E., and Meyerson, M. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304, 1497-1500.
25. Perego, P., Gatti, L., Caserini, C., Supino, R., Colangelo, D., Leone, R., Spinelli, S., Farrell, N., and Zunino, F. (1999) The cellular basis of the efficacy of the trinuclear platinum complex BBR 3464 against cisplatin-resistant cells. J. Inorg. Biochem. 77, 59-64.
26. Persons, D.L., Yazlovitskaya, E.M., Cui, W., and Pelling, J.C. (1999) Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: Inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin. Cancer Res. 5, 1007-1014.
27. Persons, D.L., Yazlovitskaya, E.M., and Pelling, J.C. (2000) Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J. Biol. Chem. 275, 35778-35785.
28. Potapova, O., Haghighi, A., Bost, F., Liu, C., Birrer, M.J., Gjerset, R., and Mercola, D. (1997) The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J. Biol. Chem. 272, 14041-14044.
29. Pratesi, G., Perego, P., Polizzi, D., Righetti, S.C., Supino, R., Caserini, C., Manzotti, C., Giuliani, F.C., Pezzoni, G., Tognella, S., Spinelli, S., Farrell, N., and Zunino, F. (1999) A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: Hypersensitivity of p53-mutant human tumour xenografts. Br. J. Cancer 80, 1912-1919.
30. Riccardi, A., Meco, D., Ferlini, C., Servidei, T., Carelli, G., Segni, G., Manzotti, C., and Riccardi, R. (2001) In vitro and in vivo antitumor activity of the novel trinuclear platinum complex BBR 3464 in neuroblastoma. Cancer Chemother. Pharmacol. 47, 498-504.
31. Roberts, J.D., Peroutka, J., Beggiolin, G., Manzotti, C., Piazzoni, L., and Farrell, N. (1999a) Comparison of cytotoxicity and cellular accumulation of polynuclear platinum complexes in L1210 murine leukemia cell lines. J. Inorg. Biochem. 77, 47-50.
32. Roberts, J.D., Peroutka, J., and Farrell, N. (1999b) Cellular pharmacology of polynuclear platinum anti-cancer agents. J. Inorg. Biochem. 77, 51-57.
33. Servidei, T., Ferlini, C., Riccardi, A., Meco, D., Scambia, G., Segni, G., Manzotti, C., and Riccardi, R. (2001) The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin. Eur. J. Cancer 37, 930-938.
34. Sessa, C., Capri, G., Gianni, L., Peccatori, F., Grasselli, G., Bauer, J., Zucchetti, M., Vigano, L., Gatti, A., Minoia, C., Liati, P., Van den Bosch, S., Bernareggi, A., Camboni, G., and Marsoni, S. (2000) Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex. Ann. Oncol. 11, 977-983.
35. Siddik, Z.H. (2003) Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7279.
36. Sorenson, C.M., Barry, M.A., and Eastman, A. (1990) Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J. Natl. Cancer Inst. 82, 749-755.
37. Tang, D., Wu, D., Hirao, A., Lahti, J.M., Liu, L., Mazza, B., Kidd, V.J., Mak, T.W., and Ingram, A.J. (2002) ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J. Biol. Chem. 277, 12710-12717.
38. Wang, X., Martindale, J.L., and Holbrook, N.J. (2000) Requirement for ERK activation in cisplatin-induced apoptosis. J. Biol. Chem. 275, 39435-39443.
39. White, L., Sterling-Levis, K., Fisher, R., and Tobias, V. (1995) Response of brain tumors to chemotherapy, evaluated in a clinically relevant xenograft model. J. Neurooncol. 25, 39-47.
40. Woessmann, W., Chen, X., and Borkhardt, A. (2002) Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines. Cancer Chemother. Pharmacol. 50, 397-404.
41. Zehnulova, J., Kasparkova, J., Farrell, N., and Brabec, V. (2001) Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair of DNA intrastrand cross-links of novel antitumor trinuclear platinum complex BBR3464. J. Biol. Chem. 276, 22191-22199.